Total: $460.252M |
||||
Company | Type Of | Number | Amount | Investors; Placement Agents; |
|
| ||||
Aastrom Biosciences | Private | N/A | $12 | Aastrom entered a deal to sell up to $12M in shares during the next 24 months to Fusion Capital Fund II LLC (12/2) |
| ||||
Advanced | Private | N/A | $0.5 | Advanced Biotherapy raised $500,000 through the private placement; the principal amount and related accrued interest is convertible to common stock at 25 cents per share, and will bear interest at 12.5% annually (12/2) |
| ||||
Alkermes Inc. | Private | N/A | $60 | Alkermes placed about $60M of its new convertible senior subordinated notes for cash to holders who participated in the exchange offer (12/26) |
| ||||
Alteon Inc. | Private | 1.7S | $3 | Alteon raised about $3M in a private placement with investors William Harris Investors Inc., DMG Advisors LLC, Merlin BioMed Private Equity Fund LP and Vertical Ventures Investments LLC (12/26) |
| ||||
Aphton Corp. | Private | 1.5S | $3.6 | Aphton raised $3.6M with the placement of 1.5M shares; Life Science Group Inc. acted as placement agent (12/3) |
| ||||
Gilead Sciences | Private | N/A | $300 | Gilead sold $300M of convertible notes to qualified institutional buyers; the notes will be convertible into Gilead common stock at $47 per share; the underwriter, Goldman Sachs & Co., has an overallotment option for an additional $45M in notes (12/13) |
| ||||
InKine | Private | N/A | $13 | InKine sold $13M worth of 10% senior secured convertible notes due June 2005 with warrants to four investors, including S.A.C. Capital Associates LLC, Royal Bank of Canada, Tail Wind Fund Ltd. and Solomon Strategic Holdings Inc. (12/17) |
| ||||
Interleukin | Installment | N/A | $0.5 | Interleukin Genetics received $500,000 as the final installment of an interim financing; the installment is in the form of a promissory note issued by Interleukin, which has received $1.5M from an unnamed consumer products company (12/17) |
| ||||
Ligand | Private | N/A | $20.25 | Ligand raised an additional $20.25M through an exercise of an overallotment option by the initial purchaser of the notes bought last month; the total raised from the placement is $155.25M (12/2) |
| ||||
Matritech | Private | 0.222U | $1.18 | Matritech raised $1.18M in a private placement of units, each consisting of 3 shares and one warrant to purchase one share (12/9) |
| ||||
MGI Pharma | Private | N/A | $21 | MGI Pharma raised $21M in a private placement of subordinated notes convertible into about 2.6M shares of common stock to affiliates of Deerfield Management Co.; MGI also issued warrants for up to 400,000 shares (12/2) |
| ||||
Neurochem | Private | 1.2U | C$8.15 | Neurochem raised US$5.22M by selling 1.2M units to a subsidiary of Picchio Pharma Inc., a joint venture between Neurochem CEO Francesco Bellini and Power Technology Investment Corp.; each unit consists of one Neurochem common share and one warrant to purchase an additional common share (12/12) |
| ||||
Nymox | Private | 0.179S | $0.713 | Nymox raised $712,500 with a private placement of 178,500 common shares (12/27) |
| ||||
Oncolytics | Private | 1U | C$2 | Oncolytics raised US$1.29M by issuing up to 1M units to Canaccord Capital Corp.; each unit consists of one common share and one-half of one common share purchase warrant (12/3) |
| ||||
Orchid | Credit facility | N/A | -- | Orchid obtained a $10M credit facility from Comerica Inc. (12/27) |
| ||||
PanGeo Pharma | Private | 1.25S | $2.5 | PanGeo raised $2.5M with the private placement of 1.25M common shares at $2 per common share to to two mutual funds under the Quebec Stock Savings Plan (12/2) |
| ||||
Procyon | Loan financing | N/A | -- | Procyon gained access to US$6.4M through a loan from Investissement Quebec; it will be able to defer the loan for up to three years from first disbursement (12/16) |
| ||||
Spectrum | Private | 0.285S and W for 0.066S | $0.599 | Spectrum raised $598,500 from three investors through the sale of 285,000 shares of stock at $2.10 per share; the investors also received five- year warrants to purchase up to 65,550 shares of common stock at an exercise price of $3.10 per share (12/19) |
| ||||
The Immune | Private | N/A | $8.4 | Immune Response raised $8.4M in a private offering of stock plus warrants (12/11) |
| ||||
Viventia | Private | 71.4U | C$10 | Viventia raised US$6.5M with a private placement of units with Leslie Dan and 1533686 Ontario Ltd., a corporation controlled by Dan's daughter; each unit consists of one common share and one common share purchase warrant (12/19) |
|
|
||||
Notes: |
||||
This chart does not include real estate or manufacturing plant financings. |
||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. |
||||
@ Dates refer to the date of the press release. |
||||
N/A = Not available, applicable or reported. |
||||
AMEX = American Stock Exchange; CDNX = Canadian Venture Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange |
||||
